Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Women
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised
controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on
change in bone mineral density over one year in women aged 50 years or older requiring
admission to intensive care for greater than 24 hours.
450 women aged 50 years or older, admitted to intensive care for greater than 24 hours will
be recruited into the study from participating study centres.
Phase:
Phase 2
Details
Lead Sponsor:
Australian and New Zealand Intensive Care Research Centre